摘要
目的比较甘精胰岛素与诺和灵N治疗初诊2型糖尿病的有效性和安全性。方法选择本院2008年1月至2009年1月初诊2型糖尿病患者60例,随机分为甘精胰岛素组(睡前皮下注射甘精胰岛素0.20 U.kg-1.d-1,1次/d)与诺和灵N组(睡前皮下注射诺和灵N 0.10～0.15 U.kg-1.d-1,1次/d),患者均在餐前给予瑞格列奈0.5 mg,3次/d。治疗3个月后比较2组患者空腹血糖(FPG)、餐后血糖(PPG)、糖基化血红蛋白(HbA1c)、低血糖发生率、治疗结束时胰岛素剂量、体质量、肝功能及肾功能。结果治疗3个月后两组患者的FPG、PPG和HbA1c均有明显下降(P<0.05);与诺和灵N组比较,甘精胰岛素组低血糖的发生率较低,治疗结束时胰岛素剂量较小(P<0.05);治疗前后组内比较,患者体质量,肝、肾功能无明显差异(P>0.05)。结论甘精胰岛素与诺和灵N均能有效控制血糖,甘精胰岛素在避免低血糖发生、血糖控制以及减少胰岛素剂量方面优于诺和灵N。
Objective To compare therapeutic effects and safety of insulin glargine and novolin N in treatment of newly-diagnosed type 2 diabetes.Methods Sixty patients newly diagnosed with type 2 diabetes from January 2008 to January 2009 in our hospital were divided randomly into a insulin glargine group（insulin glargine 0.20 U·kg^-1·d^-1ubcutaneous injection once daily at bedtime） and a novolin N group（novolin N 0.10-0.15 U·kg^-1·d^-1ubcutaneous injection once daily at bedtime）,which were all administrated with repaglinide 0.5 mg thrice daily before meals.After three months treatment,comparisons were conducted between the two groups and between before and after treatment in fasting plasma glucose（FPG）,postchallenged plasma glucose（PPG）,glycated hemoglobin Alc（HbA1c）,hypoglycemia,insulin doses at the end of treatment,body mass,liver function and renal function.Results FPG,PPG and HbA1c of patients in two groups reduced markedly after 3 months treatment（P〈0.05）.Compared with novolin N group,insulin glargine group showed lower incidence of hypoglycemia and smaller insulin dose at end of treatment（P〈0.05）.There were no significant differences between before and after treatment in two groups in patients＇ body mass,liver and renal function.Conclusion Insulin glargine and novolin N can both effectively control blood glucose.insulin glargine is superior to novolin N in preventing hypoglycemia,blood glucose controlling and reducing insulin dose.
出处
《重庆医学》
CAS
CSCD
北大核心
2011年第18期1810-1811,1814,共3页
Chongqing medicine
关键词
糖尿病
2型
胰岛素
治疗
临床研究性
diabetes mellitus
type 2
insulin
therapies
investigational
